Panbela Therapeutics (PBLA) Competitors $0.16 0.00 (0.00%) As of 07/25/2025 02:25 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. PRFX, PCSA, ARAV, GLMD, PWUP, ALZN, ADTX, PTN, JAGX, and ENTOShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include PainReform (PRFX), Heatwurx (PCSA), Aravive (ARAV), Galmed Pharmaceuticals (GLMD), PowerUp Acquisition (PWUP), Alzamend Neuro (ALZN), Aditxt (ADTX), Palatin Technologies (PTN), Jaguar Animal Health (JAGX), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors PainReform Heatwurx Aravive Galmed Pharmaceuticals PowerUp Acquisition Alzamend Neuro Aditxt Palatin Technologies Jaguar Animal Health Entero Therapeutics PainReform (NASDAQ:PRFX) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings. Does the media prefer PRFX or PBLA? In the previous week, PainReform had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Panbela Therapeutics. PainReform's average media sentiment score of 1.87 beat Panbela Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the media. Company Overall Sentiment PainReform Very Positive Panbela Therapeutics Neutral Is PRFX or PBLA more profitable? Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A Panbela Therapeutics N/A N/A -302.61% Which has more risk and volatility, PRFX or PBLA? PainReform has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Do analysts prefer PRFX or PBLA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in PRFX or PBLA? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, PRFX or PBLA? PainReform is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 SummaryPainReform beats Panbela Therapeutics on 6 of the 9 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$767K$776.92M$5.69B$9.50BDividend YieldN/A4.84%4.58%4.01%P/E Ratio0.001.4028.1020.05Price / SalesN/A25.35432.4490.07Price / CashN/A19.5636.2258.56Price / Book-0.016.798.665.87Net Income-$25.26M-$4.32M$3.25B$258.55M7 Day Performance-1.31%1.15%4.23%3.74%1 Month Performance-24.81%3.75%10.52%11.75%1 Year Performance-53.28%9.50%34.41%18.03% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.2989 of 5 stars$0.16flatN/A-53.1%$767KN/A0.006PRFXPainReform0.6889 of 5 stars$1.49-0.3%N/A-2.5%$3.00MN/A-0.014PCSAHeatwurx3.0164 of 5 stars$0.25+11.3%$2.00+700.0%-85.4%$2.97MN/A-0.0820ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumeGLMDGalmed Pharmaceuticals1.1424 of 5 stars$1.77-3.0%N/A-46.2%$2.92MN/A-0.1120News CoverageAnalyst UpgradeGap UpPWUPPowerUp AcquisitionN/A$0.36+0.6%N/A-95.4%$2.78MN/A0.00N/AGap UpHigh Trading VolumeALZNAlzamend Neuro2.6808 of 5 stars$3.23-1.1%$180.00+5,481.4%-91.5%$2.58MN/A0.004News CoverageUpcoming EarningsInsider TradeADTXAditxtN/A$1.19+0.4%N/A-100.0%$2.51M$55.32K0.0060PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeJAGXJaguar Animal Health2.8716 of 5 stars$2.38-1.2%$60.00+2,421.0%-93.4%$2.42M$11.55M0.0050ENTOEntero TherapeuticsN/A$0.51+2.5%N/A-51.0%$2.40MN/A0.009 Related Companies and Tools Related Companies PainReform Competitors Heatwurx Competitors Aravive Competitors Galmed Pharmaceuticals Competitors PowerUp Acquisition Competitors Alzamend Neuro Competitors Aditxt Competitors Palatin Technologies Competitors Jaguar Animal Health Competitors Entero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
